News | November 16, 2022
Cadila recognized for its contribution to leprosy treatment
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal
The Group will continue to make proactive investments of its management resources in the life science business
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated
